Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

7.76
-0.5000-6.05%
Post-market: 7.65-0.1100-1.42%19:47 EDT
Volume:630.95K
Turnover:4.98M
Market Cap:400.52M
PE:-2.06
High:8.35
Open:8.18
Low:7.71
Close:8.26
52wk High:16.19
52wk Low:5.04
Shares:51.61M
Float Shares:43.00M
Volume Ratio:0.55
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7593
EPS(LYR):-3.7593
ROE:-107.00%
ROA:-21.93%
PB:3.90
PE(LYR):-2.06

Loading ...

Regenxbio Inc - New Rgx-202 Data Shows Long-Term Effect at 18 Months

THOMSON REUTERS
·
Jan 12

Regenxbio Inc - Expecting FDA Pdufa Decision and Data Readouts in 2026

THOMSON REUTERS
·
Jan 12

Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says

MT Newswires Live
·
Jan 07

BofA Securities Raises Price Target on REGENXBIO to $28 From $20, Maintains Buy Rating

MT Newswires Live
·
Jan 06

REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St.
·
Dec 23, 2025

REGENXBIO Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Dec 16, 2025

BRIEF-Regenxbio Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
Nov 27, 2025

Regenxbio Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
Nov 27, 2025

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 20, 2025

Regenxbio Q3 License & Royalty Revenue USD 23.605 Million

Reuters
·
Nov 20, 2025

REGENXBIO Is Maintained at Outperform by RBC Capital

Dow Jones
·
Nov 08, 2025

Regenxbio price target raised to $25 from $24 at Morgan Stanley

TIPRANKS
·
Nov 08, 2025

RBC Capital Adjusts REGENXBIO Price Target to $19 From $17, Maintains Outperform Rating

MT Newswires Live
·
Nov 08, 2025

Stock Track | Regenxbio Plummets 5.25% Despite Beating Q3 Estimates as Losses Continue

Stock Track
·
Nov 06, 2025

Stock Track | Regenxbio Soars 6.47% Pre-market on Strong Q3 Results and Extended Cash Runway

Stock Track
·
Nov 06, 2025

Regenxbio Q3 revenue rises 23%

Reuters
·
Nov 06, 2025

Regenxbio Q3 EPS $(1.20) Beats $(1.33) Estimate, Sales $29.733M Beat $24.125M Estimate

Benzinga
·
Nov 06, 2025

Regenxbio Projects Cash Runway Into Early 2027

Reuters
·
Nov 06, 2025

BRIEF-Regenxbio Q3 License & Royalty Revenue USD 23.605 Million

Reuters
·
Nov 06, 2025

Regenxbio Q3 Operating Expenses USD 82.144 Million

THOMSON REUTERS
·
Nov 06, 2025